2007
EGFR expression by immunohistochemistry (IHC) and response to chemotherapy and cetuximab in squamous cell carcinoma of the head and neck (SCCHN)
Kies M, Ghebremichael M, Katz T, Herbst R, Youssoufian H, Burtness B. EGFR expression by immunohistochemistry (IHC) and response to chemotherapy and cetuximab in squamous cell carcinoma of the head and neck (SCCHN). Journal Of Clinical Oncology 2007, 25: 6024-6024. DOI: 10.1200/jco.2007.25.18_suppl.6024.Peer-Reviewed Original ResearchHigh EGFR expressionEGFR expressionRecurrent SCCHNTumor samplesCisplatin-based chemotherapySquamous cell carcinomaAssociation of responsePercentage of cellsHazard ratioProgressive diseaseCisplatin therapyPatient selectionCell carcinomaHigher eGFREGFR immunoreactivityInitial cohortCetuximabChemotherapyIndependent cohortFurther enrollmentPatientsSurvival analysisTumor resistanceDako kitSCCHN
2004
Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non–small-cell lung cancer: report of a randomized comparative trial
Komaki R, Lee JS, Milas L, Lee HK, Fossella FV, Herbst RS, Allen PK, Liao Z, Stevens CW, Lu C, Zinner RG, Papadimitrakopoulou VA, Kies MS, Blumenschein GR, Pisters KM, Glisson BS, Kurie J, Kaplan B, Garza VP, Mooring D, Tucker SL, Cox JD. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non–small-cell lung cancer: report of a randomized comparative trial. International Journal Of Radiation Oncology • Biology • Physics 2004, 58: 1369-1377. PMID: 15050312, DOI: 10.1016/j.ijrobp.2003.10.005.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAgranulocytosisAmifostineAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungCisplatinCombined Modality TherapyConfidence IntervalsEtoposideFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedRadiation PneumonitisRadiation-Protective AgentsRadiotherapy DosageSurvival AnalysisTreatment OutcomeConceptsArm 2 patientsCell lung cancerArm 1 patientsLung cancerArm 1Concurrent chemotherapyNational Cancer Institute Common Toxicity CriteriaConcurrent cisplatin-based chemotherapyAbility of amifostineCommon Toxicity CriteriaCisplatin-based chemotherapyTumor-protective effectMedian survival timeEffects of amifostineAcute toxicityEsophageal toxicityNeutropenic feverOral etoposideConcurrent chemoradiotherapyHematologic toxicityMild hypotensionThoracic radiotherapyLiving patientsSevere pneumonitisTumor characteristics